LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

LLY

765.18

-0.77%↓

JNJ

175.81

-0.85%↓

ABBV

220.5

-0.2%↓

UNH

341.52

+0.23%↑

AZN

76.22

-2.09%↓

Search

Roivant Sciences Ltd

Aperta

SettoreSettore sanitario

14.97 -4.95

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

14.98

Massimo

15.93

Metriche Chiave

By Trading Economics

Entrata

-22M

-274M

Vendite

-5.4M

2.2M

EPS

-0.29

Margine di Profitto

-12,622.627

Dipendenti

750

EBITDA

-284K

-284M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+24.74% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.9B

9.5B

Apertura precedente

19.92

Chiusura precedente

14.97

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Roivant Sciences Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2025, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 set 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 set 2025, 21:59 UTC

Utili

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 set 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

17 set 2025, 23:39 UTC

Discorsi di Mercato

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 set 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 set 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 set 2025, 21:00 UTC

Utili

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 set 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

17 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 set 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 set 2025, 18:43 UTC

Discorsi di Mercato

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 set 2025, 18:38 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 set 2025, 18:20 UTC

Discorsi di Mercato

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 set 2025, 18:14 UTC

Discorsi di Mercato

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 set 2025, 17:59 UTC

Discorsi di Mercato

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 set 2025, 17:15 UTC

Acquisizioni, Fusioni, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 set 2025, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 set 2025, 16:51 UTC

Utili

Correct: Exor 1H Net Loss -EUR624M

17 set 2025, 16:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 16:34 UTC

Discorsi di Mercato

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 set 2025, 16:25 UTC

Utili

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 set 2025, 16:23 UTC

Utili

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Confronto tra pari

Modifica del prezzo

Roivant Sciences Ltd Previsione

Obiettivo di Prezzo

By TipRanks

24.74% in crescita

Previsioni per 12 mesi

Media 19.06 USD  24.74%

Alto 24 USD

Basso 16 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Roivant Sciences Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

7

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

11 / 11.18Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

167 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat